Bacteria aided biopolymers as carriers for colon specific drug delivery system: A review

International Journal of PharmTech Research

Volumn 4, Issue 3, 2012, Pages 1192-1214

  Patel Parul, K ^a   Satwara Rohan, S ^a   Pandya, S S ^b  

^a Gujarat Technological University   (India)

^b B Pharmacy College   (India)

Author keywords

Biopolymer; Colon specific drug delivery system; Polysaccharides

Indexed keywords

AMIDASE; AMYLASE; AMYLOSE; AZO REDUCTASE; BACTERIUM AIDED BIOPOLYMER; BETA GALACTOSIDASE; BETA GLUCOSIDASE; BETA GLUCURONIDASE; BIOMATERIAL; BIOPOLYMER; CHITOSAN; CHONDROITIN; CHONDROITIN SULFATE; DEXTRAN; DEXTRANASE; DRUG CARRIER; ESTERASE; GLUCOSIDASE; GUAR GUM; HYALURONIC ACID; HYDROGENASE; INULIN; KARAYA GUM; NITROREDUCTASE; PECTIN; POLYGALACTURONASE; POLYSACCHARIDE; SULFATASE; UNCLASSIFIED DRUG; XANTHAN; XYLAN ENDO 1,3 BETA XYLOSIDASE;

ARTICLE; BACILLUS SUBTILIS; BACTERIAL COUNT; BACTERIAL METABOLISM; BACTEROIDES; BIFIDOBACTERIUM; BIOCOMPATIBILITY; BIODEGRADABILITY; CHEMICAL MODIFICATION; CHEMICAL STRUCTURE; CLOSTRIDIA; CLOSTRIDIUM; COLON; COLON ABSORPTION; COLONY FORMING UNIT; DRUG ABSORPTION; DRUG COATING; DRUG DELIVERY SYSTEM; DUODENUM; ENTEROCOCCUS; ENZYME RELEASE; ESCHERICHIA; ESCHERICHIA COLI; EUBACTERIACEAE; EUBACTERIUM; ILEUM; INTESTINE ABSORPTION; INTESTINE FLORA; JEJUNUM; KLEBSIELLA; KLEBSIELLA PNEUMONIAE; LACTOBACILLUS; MOLECULAR WEIGHT; NONHUMAN; STOMACH; STREPTOCOCCUS;

EID: 84870190726     PISSN: 09744304     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (126)

1. Kinget R, Kalal W, Vervoort L. and Van Den M G, Colonic drug targeting, J. Drug Target, 1998, 6, 129-49.
2. Yoshikawa Y, Hu Z, Kimura G, Murakami M, Yoshikawa H. and Takada H, A dissolution test for a pressure controlled colon delivery capsule: rotating beads method, J. Pharm. Pharmacol, 1999, 51, 979-989.
3. Sarasija S, and Hota A, Colon specific drug delivery systems, Ind. J. Pharm. Sci, 2000, 62, 1-8.
4. Schacht E, Gevaert A, El Refaie K, Koen M, Verstraete W. and Adriaensens P, Polymers for colon specific drug delivery, J. Control. Release, 1996, 39, 327-328.
5. Wilding R, Davis S. S, Pozzi F, Furlani P. and Gazzaniga A, Enteric coated timed release systems for colonic targeting, Int. J. Pharm, 1994, 111, 99-102.
6. Ravi V, Pramod K. and Siddaramaiah T. M, Novel colon targeted drug delivery system using natural polymers, Ind. J. Pharm. Sc, 2008, 70, 111-113.
7. Kararli T. T, Gastrointestinal absorption of drugs, Crit. Rev. Ther. Drug Carrier Systems. 1989, 6, 39-86.
8. J. T. Fell, Targeting of drugs and delivery system to specific sites in the gastrointestinal tract, J. Annat, 1996, 89, 517-9.
9. Patel M, Shah T. and Amin A, Therapeutic opportunities in colon specific drug delivery system, Crit. Rev. Ther. Drug Carrier. Syst, 2007, 24, 147-202.
10. Hardy J. G, Lee S. W, Clark A. G, and Reynolds, J. R, Eneme volume and spreading, Int. Jr. of Pharmaceutics, 1986, 35, 85-90.
11. Libo Yang, Bio relevant dissolution testing of colon-specific delivery systems activated by colonic microflora, Journal of Controlled Release, 2008, 125, 77-86.
12. Van den Mooter G. and Kinget R, Oral colon-specific drug delivery: A review, Drug Delivery, 1995, 2, 81-93.
13. Rama Prasad Y. V, Krishnaiah Y. S. R. and Satyanarayana S, Trends in colonic drug delivery: A review, Indian Drugs, 1996, 33, 1-10.
14. Hovgaard L, Brondsted H, Current applications of polysaccharides in colon targeting, Crit. Rev. Ther. Drug Carr. Syst, 1996, 13, 185-223.
15. Evans D. F, Pye G, Bramley R, Clark A. G, Dyson T. J, and Hardcastle J. D, Measurement of gastrointestinal pH profiles in normal ambulant human subjects, Gut, 1988, 29, 1035-41.
16. Caldwell L, Nishihata T, Rytting J. H. and Higuchi T, Lymphatic uptake of water-soluble drugs after rectal administration, J. Pharm. Pharmacol, 1982, 34, 520-522.
17. Ichihashi T, Kinoshita H. and Yamada H, Avoidance of first pass metabolism of mepitiostane by lymphatic absorption, Xenobiotica, 1991, 21, 873-880.
18. Takaya T, Niwa K. and Muraoka M, Importance of dissolution process on systemic availability of drugs delivered by colon delivery system, J. Control. Release, 1998, 50, 111-122.
19. McConnell E. L, Liu F. and Basit A. W, Colonic treatments and targets: issues and opportunities, J. Drug Target, 2009, 17, 335-363.
20. McConnell E. L, Basit A. W. and Murdan S, Colonic antigen administration induces significantly higher humoral levels of colonic and vaginal IgA, and serum IgG compared to oral administration, Vaccine, 2008, 26, 639-646.
21. Shanahan F, Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases, I, Pathophysiological basis and prospects for probiotic therapy in inflammatory bowel disease, Am J Physiol. Gastrointest. Liver Physiology, 2005, 288, G417-G421.
22. Bocci V, The neglected organ: bacterial flora has a crucial immunostimulatory role, Perspect. Biol. Med, 1992, 35, 251-260.
23. Eckburg P. B, Bik E. M, Bernstein C. N, Purdom E, Dethlefsen L, Sargent M, Gill S. R, Nelson K. E. and Relman D. A. Diversity of the human intestinal microbial flora, Science, 2005, 308, 1635-1638.
24. Cummings J. H. and Macfarlane G. T, The control and consequences of bacteria, l, Fermentation in the human colon, J. Appl. Bacteriol, 1991, 70, 443-459.
25. Francisco G. and Juan R. M. Gut flora in health and disease-Review, Lancet, 2003, 19, 361-512.
26. Scheline R. R, Metabolism of foreign compounds by gastrointestinal microorganisms, Pharmacol. Rev, 1973, 25, 451-523.
27. st Ed. New York: Marcel Dekker Inc, 2002, 871-885
28. Davis S. S, Hardy J. G. and Fara J. W, Transit of pharmaceutical dosage forms through the small intestine, Gut, 986, 27, 886-892.
29. Vonder Ohe M. R, Camilleri M, Kvols L. K. and Thomforde G. M, Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhoea, New Engl. J. Med, 1993, 329, 1073-1078.
30. Reddy S. N, Bazzocchi G, Chan S, Akashi K, Villanueva-Meyer J, Yanni G, Mena I. and Snape W. J, Jr. Colonic motility and transit in health and ulcerative colitis. Gastroenterology, 1991, 101, 1289-1297.
31. Libo Y, James S. C. and Joseph A. F, Colon-specific drug delivery: new approaches and in vitro/in vivo evaluation, International Journal of Pharmaceutics, 2002, 232, 1-15.
32. Brown J. P, Reduction of polymeric azo and nitro dyes by intestinal bacteria, Appl. Environ. Microbiol, 1981, 41, 1283-1286.
33. Kobashi K, Nishimura T, Kusaka M, Hattori M. and Namba T, Metabolism of sennosides by human intestinal bacteria, Planta. Med, 1980, 40, 237-244.
34. Rubinstein A, Microbially controlled drug delivery to the colon, Biopharm. Drug Dispos, 1990, 11, 465-475.
35. Gliko-Kabir I, Yagen B. and Penhasi A, Low swelling, crosslinked guar gum and its potential use as colon-specific drug carrier, Pharm. Res, 1998, 15, 1019.
36. Friend D. and Chang G. W, A colon-specific drug delivery based on the drug Glycosidases of colonic bacteria, J. Med. Chem, 1984, 27, 261-266.
37. Friend D. R, Glycosides in colonic drug delivery, Oral Colon-specific Drug Delivery, CRC Press, Boca Raton, 1992, Chapter 6, pp. 153-187.
38. Haeberlin B, Empey L, Fedorak R, Nolen III H, and Friend D, In vivo studies in the evaluation of glucuronide prodrugs for novel therapy of ulcerative colitis, Proceed. Intern. Symp. Control. Rel. Bioact. Mater, 1993, 20, 174-175.
39. Nolen III H, Fedorak R, and D. Friend, Glucuronide prodrugs for colonic delivery: Steady-state kinetics in conventional and colitis rats, Proceed. Intern. Symp. Control. Rel. Bioact. Mater. 1996, 23, 61-62.
40. Larsen C, Harboe E, Johansen M, and Olesen H. P, Macromolecular prodrugs: Naproxen-dextran esters, Pharm. Res. 1989, 6, 919-923, 995-999.
41. Varshosaz J, Emami J, Fassihi A. and Tavakoli N. Effectiveness of Budesonide-succinate-dextran conjugate as a novel prodrug of Budesonide against acetic acid-induced colitis in rats. International Journal of Colorectal Disease, 25, 2010, 1159-1165.
42. Salayers A. A. and Leedle J. A, Carbohydrate metabolism in the human colon. In: Hentges, D. J. (Ed.), Human Intestinal Microflora in Health and Disease, Academic Press, London, 1983, p. 129.
43. Macfarlane G. T. and Cummings J. H, The colonic flora, fermentation, and large bowel digestive function. In: Phillips, S. F, Pemberton, J. H, Shoter, R. G. (Eds.), The Large Intestine: Physiology, Pathophysiology, and Diseases. Raven Press, New York, 1991, 51-92
44. Vilivialm V. D, Illum L. and Iqbal K. Starch capsules, An alternative system for oral drug delivery, Pharm. Sci. Technol. Today, 2000, 3, 64-69.
45. Brown I. L, Conway P. L, Evans A. J, Henriksson K. A, Mcnaught K. J, Wang X, and Henriksson K. A. O. Altering gastrointestinal tract microbial populations- by administration of probiotic bacteria with optionally modified resistant starch as carrier and growth medium, useful for preventing colorectal cancer. WO 9734591-A1, 1997, 25 Sep, A61k-031/175.
46. Adriano V. R, Marcos R. G, Thais A. M, Luiz H. C. M, Edvani C. M. and Elias B. T,. Synthesis and characterization of a starch-modified hydrogel as potential carrier for drug delivery system, Journal of Polymer Science Part A: Polymer Chemistry, 2008, 46, 2567-2574.
47. Mahkam M, J. Biomed Mater. Res, 2010, 92, 1392.
48. Englyst H. N. and MacFarlane G. T, Breakdown of resistant and readily digestible starch of human gut bacteria, J. Sci. Food Agric, 1986, 37, 699-706
49. Ring S. G, Gee, J. M, Whittam M, Orford P. and Johnson, I. T, Resistant starch, Its chemical form in food stuffs and effects on digestibility in vitro, Food Chem, 1988, 28 97-109.
50. Milojevic S, Newton J. M, Cummings J. H, Gibson G. R, Botham R. L, Ring S. G, Stockham M. and Allwood M. C, Amylose as a coating for drug delivery to the colon: preparation and in vitro evaluation using 5-aminosalicylic acid pellets, J. Control Rel. 1996, 38, 75-84.
51. Siew L. F, Basit A. W. and Newton J. M, The potential of organic based amylase ethylcelulose film coatings as oral colon specific drug delivery systems, AAPS PharmSciTech, 2000 23, E22
52. Wilson P. J. and Basit A. W, Exploiting gastrointestinal bacteria to target drugs to the colon: an in vitro study using amylose coated tablets, Int. J. Pharm. 2005, 300(1-2), 89-94.
53. Simonsen L, Hovgaard L, Mortensen P. B. and Brondsted H, Dextran hydrogels for colon specific drug delivery, 5. Degradation in human intestinal incubation models. Eur. J Pharm. Sci, 1995, 3, 329-33.
54. Hovgaard L. and Brondsted H, Dextran hydrogels for colon-specific drug delivery, J. Control Rel, 1995, 36, 159-166.
55. Kunihiro M, Fumitoshi H. and Kaneto U, Colonic specific drug delivery based on cyclodextrin prodrug: Release behaviour of Biphenyl acetic acid from its cyclodextrin conjugates in rat intestinal tracts after oral administration, Journal of Pharm. Sci, 1998, 87, 715-720.
56. Juan Z, Gang C, Hirokazu O, Xiu-Hua H, Feng A, Fu-De C, Kazumi D, Colon-specific drug delivery systems based on cyclodextrin prodrugs: In vivo evaluation of 5-aminosalicylic acid from its cyclodextrin conjugates, World J. Gastroenterology, 2005, 11, 7457-7460.
57. nd Ed, 103-115.
58. Thiruganesh R, Uma Devi S. K, Himabindhu R. and Suresh S. Formulation and evaluation of xanthan gum based Aceclofenac tablets for colon targeted drug delivery, Brazilian Journal of Pharmaceutical Sciences, 2011, 47, 299-311.
59. Saito D, Nakaji S, Fukuda S, Shimoyama T, Sakamoto J. and Sugawara K, Comparison of the amount of pectin in the human terminal ileum with the amount of orally administered pectin, Nutrition, 2005, 21, 914-9.
60. Amol P, Awesh K. Y, Gopal R, Sunil K. J, Shyam S. P. and Govind P. A, Eudragit-coated Pectin Microspheres of 5-Fluorouracil for Colon Targeting, AAPS PharmSciTech, 2007, 8, Article 12
61. Liu L, Fishman M. L, Kost J. and Hicks K. B, Pectin-based systems for colon-specific drug delivery via oral route, Biomaterials, 2003, 24, 3333-43.
62. Munjeri O, Collett J. H. and Fell J. T, Hydrogel beads based on amidated pectins for colonspecific drug delivery: the role of chitosan in modifying drug release, J. Control. Rel. 1997, 46, 273-278.
63. Rubinstein A, Radai R, Ezra M, Pathak S. and Rokem J M, In vitro evaluation of calcium pectinate: A potential colon-specific drug delivery carrier, Pharm. Res, 1993, 10, 258.
64. Sriamornsak P, Prakongpan S, Puttipipatkhachorn S. and Kennedy R A, Development of sustained release theophylline pellets coated with calcium pectinate, J. Control. Rel, 1997, 47, 221-232.
65. Wong T. W, Gaia C. and Fabio S, Pectin Matrix as Oral Drug Delivery Vehicle for Colon Cancer Treatment, AAPS PharmSciTech, 2011, 12, 201-214.
66. Surajit D, Ka-Yun N. and Paul C. Ho, Formulation and Optimization of Zinc-Pectinate Beads for the Controlled Delivery of Resveratrol, AAPS PharmSciTech, 2010, 11 729-742.
67. Tomlin A, Read N. W, Edwards C. A. and Duerden B. I, The degradation of guar gum by a fecal incubation system, Br. J. Nutr, 1986, 55, 481-486.
68. Wong D, Larrabee S, Clifford K, Tremblay J. and Friend D R, USP dissolution apparatus III (reciprocating cylinder) for screening of guar-based colonic delivery formulations, J. Control. Rel, 1997, 47, 173-179.
69. Krishnaiah Y S R, Satyanarayana S, Prasad Y V R. and Rao S N, Gamma Scintigraphic studies on guar gum matrix tablets for colonic drug delivery in healthy human volunteers, J. Control. Rel, 1998, 55, 245-252.
70. Krishnaiah Y S R, Veer Raju P, Dinesh Kumar B, Satyanarayana V, Karthikeyan R S, and Bhaskara P, Pharmacokinetic evaluation of guar gum based colon targeted drug delivery system of mebendazole in healthy volunteers, J. Control. Rel, 2003, 88, 95-103.
71. Krishnaiah Y S R, Veer Raju P, Dinesh Kumar B, Satyanarayana V, Karthikeyan R S, and Bhaskara P, In vivo pharmacokinetics in human volunteers: orally administered guar gum based colon targeted 5-flurouracil tablets, Eur. J. Pharm. Sci, 2003, 19, 355-362.
72. Rubinstein A. and Gliko-Kabir I, Synthesis and swelling dependent enzymatic degradation of borax modified guar gum for colonic delivery purposes, STP Pharma. Sci, 1995, 5, 41-46.
73. Ji C. M, Xu H. N. and Wu W, Guar gum as potential film coating material for colon specific delivery of 5-Fluorouracil, J. Biomater. Appl, 2009, 23, 311-329.
74. Laila Fatima A. A, Chetan B. C. and Sajeev C, Assessment of suitability of guar gum with pH sensitive polymer matrix bases for colon specific delivery, Der Pharmacia Lettre, 2011, 3, 425-441.
75. Chaurasia M, Chourasia M. K, Jain N. K, Jain A, Soni V, Gupta Y. and Jain S. K, Cross-Linked Guar Gum Microspheres: A Viable Approach for Improved Delivery of Anticancer Drugs for the Treatment of Colorectal Cancer, AAPS PharmSciTech 2006, 7, Article 74.
76. Vervoort L. and Kinget R, In vitro degradation by colonic bacteria of inulin HP incorporated in Eudragit RS films, Int. J. Pharm, 1996, 129, 185-190.
77. Vervoort L, Vanden M. G, Augustins P, Bousson R, Toppet S, Kinget R, Inulin hydrogels as carriers for colonic drug targeting. I. Synthesis and characterization of methacrylated inulin and hydrogen formation, Pharm. Res, 1997, 14, 1730-1737.
78. Vervoort L, Rombaut P, Vanden M. G, Augustins P. and Kinget R, Inulin hydrogels. II. In vitro degradation study, Int. J. Pharm. 1998, 172, 137-145.
79. Castelli F, Sarpietro M. G, Micieli D, Ottim S, Pitarresi G, Tripodo G, Carlisi B. and Giammona G, Differential scanning calorimetry study on drug release from an inulin-based hydrogel and its interaction with a biomembrane model: pH and loading effect, Eur. J. Pharm. 2008, 35, 76-85.
80. Le Cerf D, Irinei F. and Muller G, Solution properties of gum exudates from Sterculia urens (karaya gum), Carbohydr. Polym, 1990, 13, 375-386.
81. Weiping W, Tragacanth and karaya, In: Philips G. O, Williams P. A. (eds) Handbook of hydrocolloids. Woodhead, Cambridge, 2000, 155-168.
82. Whistler R L, Exudate gums. In: Whistler R. L, Bemiller J. N. (eds) Industrial gums: polysaccharides and their derivatives. Academic Press, San Diego, 1993, 318-337.
83. Marta Izydorczyk, Steve W. Cui, and Qi Wang. Food carbohydrate-Chemistry, physical properties and application Polysaccharide Gums: Structures, Functional Properties and Applications. Edited by published by CRC press, 2005.
84. Singh B. B. and Sharma N. N, Modification of sterculia gum with methacrylic acid to prepare a novel drug delivery system, Int. J. Biol. Macromol, 2008, 43, 142-50
85. Singh B. B. and Sharma N. N, Mechanistic Implication for Cross-Linking in Sterculia-Based Hydrogels and Their Use in GIT Drug Delivery, Biomacromolecules, 2009, 10, 2515-2532.
86. Amrutkar J. R. and Gattani S. G, Jr. of Microencapsulation, 2012, 29, 72-82
87. Glicksman M., Mrak E. M. and Stewart G. F, Utilization of natural polysaccharide gums in the food industry. Advances in food research, vol 2, Academic Press: New York, NY, USA; pp. 110-191,
88. Raghavan C. V, Muthulingam C, Jenita J. A. and Ravi T. K, An in vitro and in vivo investigation into the suitability of bacterially triggered delivery system for colon targeting. Chem. Pharm. Bull, 2002, 50, 892-5.
89. González C. A, Fernández M. N, Sahagún A. M, García V. J. J, Díez L. M. J, Calle Pardo A. P, Castro R. L. J, Sierra V. M, Glucomanan: Properties and Therapeutic applications, Nutr. Hosp. 2004, 19, 45-50.
90. Dave V, Sheth M, McCarthy S. P, Ratto J. A. and Kaplan D. L, Liquid crystalline, rheological and thermal properties of konjac glucomannan, Polymer, 1998, 39(5), 1139-1148.
91. Nakano M, Takikawa K. and Arita T, Release characteristics of dibucaine dispersed in konjac gels, J. Biomed. Mater. Res, 1979, 13, 811-919.
92. Liu M. M, Fan J. Y, Wang K. and He Z. M, Synthesis, characterization, and evaluation of phosphated cross-linked konjac glucomannan hydrogels for colon-targeted drug delivery. Drug Delivery, 2007, 14, 397-402.
93. Wang K, Fan J. Y, Yanjun Y. J. and He Z. M, Konjac glucomannan and xanthan gum as compression coat for colonic drug delivery: experimental and theoretical evaluations, Front. Chem. Eng. China, 2010, 4, 102-108.
94. Alvarez-Manceñido F, Landin M. and Martínez-Pacheco R, Konjac glucomannan/ xanthan gum enzyme sensitive binary mixtures for colonic drug delivery, Eur. J. Pharm. Biopharm, 2008, 69, 573-81.
95. Prabhu P, Ahamed N, Matapady H. N, Ahmed M. G, Narayanacharyulu R, Satyanarayana D. and Subrahmanayam E, Investigation and Comparison of Colon Specificity of Novel Polymer Khaya Gum with Guar Gum, Pak. J. Pharm. Sci, 2010, 23, 259-265.
96. Oluwatoyin A. and Odeku J. T. F, In-vitro evaluation of khaya and albizia gums as compression coatings for drug targeting to the colon, Journal of Pharmacy and Pharmacology, 2005, 57, 163-168
97. Rubinstein A, Nakar D. and Sintov A, Colonic drug delivery: enhanced release of indomethacin from cross-linked chondroitin matrix in rat cecal content, Pharm. Res, 1992, 9, 276-278.
98. Amrutkar J. R. and Gattani S. G, Chitosan-Chondroitin Sulfate Based Matrix Tablets for Colon Specific Delivery of Indomethacin, AAPS PharmSciTech, 2009, 10, 670-677.
99. Thiruganesh R, Uma devi S. K. and Suresh S, Formulation and Evaluation of Chondroitin Sulphate Tablets of Aceclofenac for Colon Targeted Drug Delivery, Jr. of phrm. res. and health care, 2010, 2, 46-65
100. No H. K. and Meyers S. P, Utilization of Crawfish Processing Wastes as Carotenoids, Chitin, and Chitosan Souces, J. Kor. Soc. Food Nutr, 1992, 21, 319-326.
101. Knorr D, Use of chitinous polymers in food. A challenge for food research and development, Food Technol, 1984, 38, 85-97.
102. No H. K. and Meyers S. P, Preparation and Characterization of Chitin and Chitosan-A Review. J. Aquat. Food Prod. Technol. 1995, 4, 27-52.
103. Knaul J. Z, Hudson S. M. and Creber K. A. M, Crosslinking of chitosan fibers with dialdehydes: Proposal of a new reaction mechanism J. Polym. Sci. B: Polym. Phys. 37, 1999, 1079-1094.
104. Li Q, Dunn E. T, Grandmaison E. W. and Goosen M. F. A, Applications and properties of chitosan, J. Bioact. Compat. Polym, 1992, 7, 370-397.
105. Tominaga S, Takizawa T. and Yamada M, Large intestinal delivery composite. US patent 6, 2001, 248, 362.
106. Hideyuki T, Junta K, Chika T, Takako M, Akira T, Tsutomu S, Akira Y. and Shozo M, Chitosan capsule for colon-specific drug delivery: Improvement of insulin absorption from the rat colon, Jr. Pharm. Sci, 1997, 86, 1016-1021.
107. Lorenzo-Lamosa M. L, Remunan-Lopez C, J. L. Vila-Jato J. L. and Alonso M. J, Design of microencapsulated chitosan microspheres for colonic drug delivery, J. Control. Release, 1998, 52, 109-118.
108. Liu H, Yang X. G, Nie S. F, Wei L. L, Zhou L. L, Tang R. and Pan W. S, Chitosan-based controlled porosity osmotic pump for colon-specific delivery system: Screening of formulation variables and in vitro investigation. International Journal of Pharmaceutics, 2007, 332, 115-124.
109. Necas J, Bartosikova L, Brauner P. and Kolar J, Hyaluronic acid (hyaluronan): a review, Veterinarian Medicinal, 2008, 53, 397-411.
110. O'Regan M, Martini I, Crescenzi F, De Luca C. and Lansing M, Molecular mechanisms and genetics of hyaluronan biosynthesis, International Journal of Biological Macromolecules, 1994, 16, 283-286.
111. Brown M. B. and Jones S. A, Hyaluronic acid: a unique topical vehicle for the localized delivery of drugs to the skin, Journal of European Academy of Dermatology and Venereology, 19 (2005) 308-318.
112. Moreland L. W, Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: mechanisms of action, Arthritis Research and Therapy, 2003, 5, 54-67.
113. Toole B. P, Wight T. N. and Tammi M. I, J. Biol. Chem, 2002, 277, 4593.
114. Yang B, Zhang L. and Turley E. A, J. Biol. Chem, 1993, 268, 8617.
115. Day A. J. and Prestwich G. D, J. Biol. Chem, 2002, 277, 4585.
116. Turley E. A, Belch A. J, Poppema S. and Pilarski L. M, Blood, 1993, 81, 446.
117. Liu N, Gao F, Han Z, Xu X, Underhill C. B. and Zhang L. Cancer Res. 2001, 6, 5207.
118. Zeng C, Toole B. P, Kinney S. D, Kuo J. and Stamenkovic I, Int. J. Cancer, 1998, 177 396.
119. Coradini D, Pellizzaro C, Miglierini G, Daidone M. G. and Perbellini A, Int. J. Cancer, 1999, 81, 411.
120. Luo Y, Ziebell M. R. and Prestwich G. D, Biomacromolecules. 2001, 1, 208.
121. Luo Y, Bernshaw N. J, Lu Z.-R, Kopecek J. and Prestwich G. D, Pharm. Res, 2002, 19, 396.
122. Jain A, Jani S. K, Ganesh N, Barve J. and Aadil M. B, Design and development of ligand-appended polysaccharidic nano particles for the delivery of oxaliplatin in colorectal cancer, Nanomedicine: Nano technology, Biology and Medicine, 2010, 6, 179-190.
123. Aquilera J. M. and Stanley D. W, Micro structural principles of food processing and engineering, Springer: Aspen, Germany, 1999, 99-103.
124. Ching, A. L, Liew C. V, Heng P. W. S, Chan L. W, Impact of cross-linker on alginate matrix integrity and drug release, Int. J. Pharm, 2008, 355, 259-268.
125. Xu Y, Zhan C, Fan L, Wang L. and Zheng H, Preparation of dual crosslinked alginate-chitosan blend gel beads and in vitro controlled release in oral site-specific drug delivery system, Int J Pharm. 2007, 336, 329-37. Epub 2006 Dec 20.
126. Wakerly Z, Fell J, Attwood D. and Parkins D, Studies on amidated pectins as potential carriers in colonic drug delivery, J. Pharm. Pharmacol. 1997, 49, 622-5.